Medical Oncology最新文献_第4页

The impact of apoptosis-inducing MAPK and glycolytic pathways modulated by Aloe vera and royal jelly in lung and colorectal cancer. 芦荟和蜂王浆对诱导凋亡的MAPK和糖酵解通路在肺癌和结直肠癌中的影响。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-21 DOI: 10.1007/s12032-025-02606-7

Tuğba Kul Köprülü, Bahar Gezer, Burçin Erkal Çam

{"title":"The impact of apoptosis-inducing MAPK and glycolytic pathways modulated by Aloe vera and royal jelly in lung and colorectal cancer.","authors":"Tuğba Kul Köprülü, Bahar Gezer, Burçin Erkal Çam","doi":"10.1007/s12032-025-02606-7","DOIUrl":"10.1007/s12032-025-02606-7","url":null,"abstract":"Lung and colon cancer are among the most commonly diagnosed and fatal cancer types in the world. Due to their metastatic properties, they complicate the treatment process and pose a great threat to human health. These aggressive types of cancer are resistant to chemotherapy drugs. Therefore, it is extremely important to investigate the therapeutic effects of natural compounds. In our previous study, effective doses of Royal Jelly (RJ) (100 mg/mL) and Aloe vera (AVE) (20 µg/mL) were determined and tested separately and in combination on lung and colorectal cancer cells. Glycolytic capacities were determined using the Seahorse XFe24 Analyzer, total transcriptome profiles were sequenced using NovaSeq 6000, and BAX and BCL-2 gene levels were determined using RT-qPCR. It was seen that RJ and RJ + AVE affected glycolytic capacity and more genes in lung cancer cells. In HT29, AVE alone was seen to reduce glycolytic capacity and RJ + AVE combination was seen to reduce the expression level of genes related to cell proliferation and cycle. After RJ + AVE treatments, the apoptotic process which is triggered via MAPK pathway was found in lung cancer. Moreover, BAX levels increased and BCL-2 levels decreased both lung and colorectal cancer cells. It was observed that the combination of RJ and AVE affected the glycolysis process, cell cycle, proliferation and apoptosis on lung and colorectal cancer. In particular, the combination of RJ + AVE was found to be more effective on lung cancer.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 2","pages":"51"},"PeriodicalIF":2.8,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanotechnology-based biomedical devices in the cancer diagnostics and therapy. 基于纳米技术的生物医学设备在癌症诊断和治疗中的应用。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-20 DOI: 10.1007/s12032-025-02602-x

Junaid Tantray, Akhilesh Patel, Hiba Parveen, Bhupendra Prajapati, Jigna Prajapati

{"title":"Nanotechnology-based biomedical devices in the cancer diagnostics and therapy.","authors":"Junaid Tantray, Akhilesh Patel, Hiba Parveen, Bhupendra Prajapati, Jigna Prajapati","doi":"10.1007/s12032-025-02602-x","DOIUrl":"10.1007/s12032-025-02602-x","url":null,"abstract":"Nanotechnology has significantly transformed the field of cancer diagnostics and therapeutics by introducing advanced biomedical devices. These nanotechnology-based devices exhibit remarkable capabilities in detecting and treating various cancers, addressing the limitations of traditional approaches, such as limited specificity and sensitivity. This review aims to explore the advancements in nanotechnology-driven biomedical devices, emphasizing their role in the diagnosis and treatment of cancer. Through a comprehensive analysis, we evaluate various nanotechnology-based devices across different cancer types, detailing their diagnostic and therapeutic effectiveness. The review also discusses FDA-approved nanotechnology products, patents, and regulatory trends, highlighting the innovation and clinical impact in oncology. Nanotechnology-based devices, including nanobots, smart pills, and multifunctional nanoparticles, enable precise targeting and treatment, reducing adverse effects on healthy tissues. Devices such as DNA-based nanorobots, quantum dots, and biodegradable stents offer noninvasive diagnostic and therapeutic options, showing high efficacy in preclinical and clinical settings. FDA-approved products underscore the acceptance of these technologies. Nanotechnology-based biomedical devices offer a promising future for oncology, with the potential to revolutionize cancer care through early detection, targeted treatment, and minimal side effects. Continued research and technological improvements are essential to fully realize their potential in personalized cancer therapy.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 2","pages":"50"},"PeriodicalIF":2.8,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GRP78 as a potential therapeutic target in cancer treatment: an updated review of its role in chemoradiotherapy resistance of cancer cells. GRP78作为癌症治疗的潜在治疗靶点：其在癌细胞放化疗耐药中的作用的最新综述

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-18 DOI: 10.1007/s12032-024-02586-0

Min Lin, Yan Mo, Cheng-Min Li, Ying-Zhe Liu, Xue-Ping Feng

{"title":"GRP78 as a potential therapeutic target in cancer treatment: an updated review of its role in chemoradiotherapy resistance of cancer cells.","authors":"Min Lin, Yan Mo, Cheng-Min Li, Ying-Zhe Liu, Xue-Ping Feng","doi":"10.1007/s12032-024-02586-0","DOIUrl":"10.1007/s12032-024-02586-0","url":null,"abstract":"GRP78 (Glucose-related protein 78, BiP/HSPA5) is commonly overexpressed in cancer cells. Acting as an activator of endoplasmic reticulum stress, GRP78 is involved in the resistance of cancer cells to injury. Current evidence suggests that GRP78 plays a significant role in the radiotherapy resistance and chemotherapy resistance of cancers, which is accomplished through a variety of complex pathways. These include the promotion of tumor stemness, inhibition of apoptosis, regulation of autophagy, maintenance of tumor microenvironment homeostasis, protection of dormant cells, evasion of senescence, counteraction of autoantibodies against GRP78, facilitation of DNA damage repair, suppression of ferroptosis, and modulation of metabolic reprogramming in tumor cells. Importantly, chemoradiotherapy resistance in cancers are the main reasons for treatment failure in patients, severely affecting their survival. Investigating the mechanisms of GRP78 in tumor therapeutic resistance is essential. In this article, we review the mechanisms by which GRP78 mediates cell survival and chemoradiotherapy resistance in cancers and provide an overview of clinical trials targeting GRP78 therapy.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 2","pages":"49"},"PeriodicalIF":2.8,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protocatechuic aldehyde sensitizes BRAF-mutant melanoma cells to temozolomide through inducing FANCD2 degradation.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-18 DOI: 10.1007/s12032-025-02601-y

Jie Yang, Xin Zeng, Junxia Pei, Zhou Su, Qi Liu, Yamei Zhang, Yixi Yang, Rui Li, Fei Zhou, Yu Deng

引用次数: 0

Boric acid impedes glioblastoma growth in a rat model: insights from multi-approach analysis. 硼酸在大鼠模型中阻碍胶质母细胞瘤的生长：来自多方法分析的见解。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-17 DOI: 10.1007/s12032-025-02600-z

Hasan Turkez, Fatih Alper, Cemil Bayram, Cem Baba, Edanur Yıldız, Melik Saracoglu, Muhammed Kucuk, Berrah Gozegir, Metin Kiliclioglu, Mustafa Yeşilyurt, Ozlem Ozdemir Tozlu, Ismail Bolat, Serkan Yildirim, Muhammed Furkan Barutcigil, Fatih Isik, Özlem Kiki, Fahri Aydın, Mehmet Enes Arslan, Kenan Cadircı, Adem Karaman, Abdulgani Tatar, Ahmet Hacımüftüoğlu

{"title":"Boric acid impedes glioblastoma growth in a rat model: insights from multi-approach analysis.","authors":"Hasan Turkez, Fatih Alper, Cemil Bayram, Cem Baba, Edanur Yıldız, Melik Saracoglu, Muhammed Kucuk, Berrah Gozegir, Metin Kiliclioglu, Mustafa Yeşilyurt, Ozlem Ozdemir Tozlu, Ismail Bolat, Serkan Yildirim, Muhammed Furkan Barutcigil, Fatih Isik, Özlem Kiki, Fahri Aydın, Mehmet Enes Arslan, Kenan Cadircı, Adem Karaman, Abdulgani Tatar, Ahmet Hacımüftüoğlu","doi":"10.1007/s12032-025-02600-z","DOIUrl":"10.1007/s12032-025-02600-z","url":null,"abstract":"Limited advancements in managing malignant brain tumors have resulted in poor prognoses for glioblastoma (GBM) patients. Standard treatment involves surgery, radiotherapy, and chemotherapy, which lack specificity and damage healthy brain tissue. Boron-containing compounds, such as boric acid (BA), exhibit diverse biological effects, including anticancer properties. This study aimed to examine whether boron supplementation, as BA, can inhibit glioblastoma growth in a xenograft animal model. Using MRI-based tumor size measurement, survival rates, hematological, clinical biochemistry analyses, and genotoxicity parameters, we assessed the impact of BA. Histopathological, immunohistochemical, and immunofluorescence examinations were also conducted. All BA doses (3.25, 6.5, and 13 mg kg-1 b.w.) extended survival compared to GBM controls after 14 days, with a dose-dependent anti-GBM effect observed in MRI analyses. BA treatment improved hematological (WBC and PLT counts) and biochemical parameters (LDL-C, CREA, and ALP). Histopathological examination revealed a significant reduction in tumor diameter with 6.5 and 13 mg kg-1 BA. Immunohistochemical and immunofluorescence staining showed modulation of intracytoplasmic Ki67, cytoplasmic CMPK2, and GFAP expressions in tumor cells post-BA treatment. Additionally, BA did not increase micronuclei formations, indicating its non-genotoxic nature. In conclusion, targeting tumor suppressor networks with boron demonstrates significant therapeutic potential for GBM treatment.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 2","pages":"47"},"PeriodicalIF":2.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging nanoplatforms towards microenvironment-responsive glioma therapy. 新兴的微环境反应性胶质瘤治疗纳米平台。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-15 DOI: 10.1007/s12032-024-02596-y

Nigam Sekhar Tripathy, Liza Sahoo, Safal Paikray, Fahima Dilnawaz

{"title":"Emerging nanoplatforms towards microenvironment-responsive glioma therapy.","authors":"Nigam Sekhar Tripathy, Liza Sahoo, Safal Paikray, Fahima Dilnawaz","doi":"10.1007/s12032-024-02596-y","DOIUrl":"10.1007/s12032-024-02596-y","url":null,"abstract":"Gliomas are aggressive intracranial tumors of the central nervous system with a poor prognosis, high risk of recurrence, and low survival rates. Radiation, surgery, and chemotherapy are traditional cancer therapies. It is very challenging to accurately image and differentiate the malignancy grade of gliomas due to their heterogeneous and infiltrating nature and the obstruction of the blood-brain barrier. Imaging plays a crucial role in gliomas which significantly plays an important role in the accuracy of the diagnosis followed by any subsequent surgery or therapy. Other diagnostic methods (such as biopsies or surgery) are often very invasive. Preoperative imaging and intraoperative image-guided surgery perform the most significant safe resection. In recent years, the rapid growth of nanotechnology has opened up new avenues for glioma diagnosis and treatment. For better therapeutic efficacy, developing microenvironment-responsive nanoplatforms, including novel nanotherapeutic platforms of sonodynamic therapy, photodynamic therapy, and photothermal treatments, are employed for improved patient survival and better clinical control outcome. In this review recent advancement of multifunctional nanoplatforms leading toward treatment of glioma is discussed.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 2","pages":"46"},"PeriodicalIF":2.8,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PYGO2 promotes resistance to chemotherapy via reducing apoptosis and G2/M cell cycle arrest in esophageal carcinoma cells. PYGO2通过减少食管癌细胞凋亡和G2/M细胞周期阻滞促进化疗耐药。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-14 DOI: 10.1007/s12032-024-02590-4

Fatemeh Ardalan Moghadam Al, Mohammad Mahdi Forghanifard, Vajiheh Zarrinpour

{"title":"PYGO2 promotes resistance to chemotherapy via reducing apoptosis and G2/M cell cycle arrest in esophageal carcinoma cells.","authors":"Fatemeh Ardalan Moghadam Al, Mohammad Mahdi Forghanifard, Vajiheh Zarrinpour","doi":"10.1007/s12032-024-02590-4","DOIUrl":"10.1007/s12032-024-02590-4","url":null,"abstract":"5-FU is a widely used chemotherapy drug for esophageal carcinomas, but therapy failure has been observed in 5-FU-resistant patients. Overcoming this resistance is a significant challenge in cancer treatment, requiring identifying and targeting important resistance mechanisms. PYGO2 expression is crucial in developing resistance to various chemotherapy drugs. In this study, we aimed to investigate the impact of PYGO2 overexpression on the sensitivity of YM-1 and KYSE-30 esophageal carcinoma cells against 5-FU. To do this, we compared cell viability, cell cycle arrest, apoptosis rate, and mRNA expressions of various apoptosis-related genes between pcDNA3-PYGO2 transfected and untransfected KYSE-30 and YM-1 esophageal carcinoma cells following treatment with 5-FU. We showed that PYGO2 expression reduces 5-FU sensitivity in YM-1 and KYSE-30 cells. PYGO2-overexpressing cells treated with 5-FU have exhibited a noteworthy reduction in both early and late apoptotic cells compared to controls. Furthermore, a significant decrease in the Bax/Bcl2 ratio and P53 gene expression was observed. 5-FU induces G2/M cell cycle arrest in YM-1 and KYSE-30 cells. However, PYGO2 overexpression impeded G2/M cell cycle arrest in 5-FU-treated cells, thereby suppressing the toxicity of 5-FU. PYGO2 may mediate its apoptotic effect by regulating cell cycle regulatory proteins, specifically cyclin D1 and p21. These results highlight PYGO2's capacity to alter how esophageal cancer cells respond to 5-FU therapy, emphasizing its importance as a potential focal point for treatment strategies.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 2","pages":"45"},"PeriodicalIF":2.8,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in surgical management of chronic lymphedema: current strategies and future directions. 慢性淋巴水肿的外科治疗进展：当前策略和未来方向。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-13 DOI: 10.1007/s12032-024-02576-2

Sai Anusha Sanka, Sophia Chryssofos, Rachel A Anolik, Justin M Sacks

{"title":"Advances in surgical management of chronic lymphedema: current strategies and future directions.","authors":"Sai Anusha Sanka, Sophia Chryssofos, Rachel A Anolik, Justin M Sacks","doi":"10.1007/s12032-024-02576-2","DOIUrl":"10.1007/s12032-024-02576-2","url":null,"abstract":"Lymphedema is a chronic condition caused by the accumulation of protein-rich fluid in the interstitial tissue, resulting in edema and a diminished quality of life. When first-line treatments like complete decongestive therapy (CDT) fail, surgical options are considered. These include physiological procedures like lymphaticovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT), which aim to restore lymphatic function, as well as reductive procedures such as liposuction and excisional techniques, which reduce limb volume. Previous studies have evaluated these surgeries, but the literature remains scattered. This rapid review consolidates current research on surgical treatments for lymphedema. We reviewed the PubMed database and included systematic reviews, meta-analyses, randomized clinical trials, and literature reviews published between 2014 and 2024. Studies were selected if they reported outcomes such as objective volume reduction, patient-reported quality of life (QOL), or infection rates. Nineteen publications were selected for review. The most common procedures represented were LVA (N = 12) and VLNT (N = 10), though reductive operations such as liposuction and radical excision were also represented. Both LVA and VLNT, either alone or combined, demonstrated positive outcomes in terms of volume reduction, QOL, and infection prevention. Reductive surgeries were effective in reducing long-term volume but had less favorable cosmetic outcomes and variable infection rates. Overall, while surgical approaches have proven beneficial, the variability in outcome measures and inconsistent follow-up periods limit comparability across studies. Further research is needed to better guide patients in selecting the most appropriate surgical option based on their lymphedema characteristics and personal goals.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 2","pages":"44"},"PeriodicalIF":2.8,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Didemnins as marine-derived anticancer agents: mechanistic insights and clinical potential. dideminins作为海洋来源的抗癌药物：机理和临床潜力。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-11 DOI: 10.1007/s12032-024-02594-0

Muhammad Asif Ali, Azmat Ullah Khan, Ahmad Ali, Muniba Khaliq, Noohela Khan, Sania Mujahid, Daniela Calina, Mirosława Püsküllüoğlu, Javad Sharifi-Rad

{"title":"Didemnins as marine-derived anticancer agents: mechanistic insights and clinical potential.","authors":"Muhammad Asif Ali, Azmat Ullah Khan, Ahmad Ali, Muniba Khaliq, Noohela Khan, Sania Mujahid, Daniela Calina, Mirosława Püsküllüoğlu, Javad Sharifi-Rad","doi":"10.1007/s12032-024-02594-0","DOIUrl":"10.1007/s12032-024-02594-0","url":null,"abstract":"Didemnins, a class of cyclic depsipeptides derived from marine organisms exhibit notable anticancer properties. Among them, Didemnin B has been extensively researched for its strong antitumor activity and progression to clinical trials. Nonetheless, its clinical application has been impeded by challenges like poor bioavailability and dose-limiting toxicity. This review aims to provide a comprehensive analysis of the anticancer mechanisms of Didemnins, particularly Didemnin B, by examining studies that investigate their anticancer properties, mechanisms of action, pharmacokinetics, and clinical outcomes, while exploring their potential as therapeutic agents in cancer treatment. A comprehensive review of the literature was conducted using scientific databases, including PubMed, Google Scholar and ScienceDirect. Didemnin B has been shown to exert its anticancer effects primarily through the inhibition of protein synthesis, induction of apoptosis, and disruption of cell-cycle progression. Despite promising preclinical results, clinical trials have revealed substantial toxicity, particularly neuromuscular and hepatic, which significantly constrains its therapeutic potential. Recent progress in developing semisynthetic derivatives, including Dehydrodidemnin B (Plitidepsin, Aplidin), have led to improved efficacy and reduced toxicity. Didemnins, especially Didemnin B, hold promise as anticancer agents. However, future research should focus on optimizing delivery methods, reducing toxicity, and exploring combination therapies to enhance their therapeutic potential in oncology.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 2","pages":"43"},"PeriodicalIF":2.8,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platinum nanoparticles in cancer therapy: chemotherapeutic enhancement and ROS generation. 铂纳米颗粒在癌症治疗中的作用：化疗增强和ROS的产生。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-09 DOI: 10.1007/s12032-024-02598-w

Emmanuel Faderin, Terungwa H Iorkula, Omowunmi Rebecca Aworinde, Raymond Femi Awoyemi, Christopher Taiwo Awoyemi, Edward Acheampong, Janefrances U Chukwu, Peter Agyemang, Gregory E Onaiwu, Ikhazuagbe Hilary Ifijen

{"title":"Platinum nanoparticles in cancer therapy: chemotherapeutic enhancement and ROS generation.","authors":"Emmanuel Faderin, Terungwa H Iorkula, Omowunmi Rebecca Aworinde, Raymond Femi Awoyemi, Christopher Taiwo Awoyemi, Edward Acheampong, Janefrances U Chukwu, Peter Agyemang, Gregory E Onaiwu, Ikhazuagbe Hilary Ifijen","doi":"10.1007/s12032-024-02598-w","DOIUrl":"10.1007/s12032-024-02598-w","url":null,"abstract":"Platinum nanoparticles (PtNPs) offer significant promise in cancer therapy by enhancing the therapeutic effects of platinum-based chemotherapies like cisplatin. These nanoparticles improve tumor targeting, reduce off-target effects, and help overcome drug resistance. PtNPs exert their anti-cancer effects primarily through the generation of reactive oxygen species (ROS), which induce oxidative stress and apoptosis in cancer cells. Additionally, PtNPs interact with cellular signaling pathways such as PI3K/AKT and MAPK, sensitizing cancer cells to chemotherapy. Advances in PtNP synthesis focus on optimizing size, shape, and surface modifications to enhance biocompatibility and targeting. Functionalization with biomolecules allows selective tumor delivery, while smart release systems enable controlled drug release. In vivo studies have shown that PtNPs significantly inhibit tumor growth and metastasis. Ongoing clinical trials are evaluating their safety and efficacy. This review explores PtNPs' mechanisms of action, nanotechnology advancements, and challenges in biocompatibility, with a focus on their potential integration into cancer treatments.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 2","pages":"42"},"PeriodicalIF":2.8,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0